Orchid Pharma Limited (ORCHPHARMA) has recently unlocked two massive, fundamental corporate and commercial catalysts that have triggered significant upward momentum for the stock:💊 The $178 Million Russian Commercialization Deal (July 2026): Orchid Pharma signed a major, exclusive licensing and supply agreement with Russian pharmaceutical giant Pharmasyntez JSC to commercialize its patented flagship antibiotic, Exblifep (a novel drug treating severe hospital infections and UTIs). Pharmasyntez will handle exclusive registration and marketing across Russia, while Orchid will handle sole manufacturing and supply. This 10-year deal represents a potential $178 million revenue opportunity, leveraging the fact that Exblifep is already approved by the USFDA and EMA. ⚖️ Final NCLT Sanction for Dhanuka Laboratories Merger (June–July 2026): The National Company Law Tribunal (NCLT) issued its final order approving the structural amalgamation of promoter entity Dhanuka Laboratories Limited into Orchid Pharma. The company fixed July 23, 2026, as the official Record Date for alloting shares to Dhanuka’s shareholders. Backdated to an appointed date of April 1, 2024, this consolidation unites their API research assets and product portfolios, with management targeting combined forward annual revenues of ₹1,400–₹1,500 crore and EBITDA of ₹200–₹250 crore. These catalysts—bridging large-scale global product commercialization with massive domestic operational consolidation—have significantly strengthened Orchid Pharma's medium-term earnings outlook.
관련 발행물
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
관련 발행물
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.